Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib Open-Label Extension in Rheumatoid Arthritis
NCT02983227Phase 2Completed
- Sponsor
- Genentech
- Start
- Nov 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of fenebrutinib in rheumatoid arthritis (RA) (2 cohorts), sponsored by Genentech. Primary endpoints: Percentage of Participants With Adverse Events and Percentage of Participants Achieving American College of Rheumatology 50% Response at Week 52. Started Nov 2016; status: completed.
02
Drugs
fenebrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02983227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983227.